Generate a tailored SOP for Dr. Branimir Sikic. Improve your application with a focused, well-structured draft.
Branimir I. Sikic, M. D., is a Professor of Medicine in the Division of Oncology at Stanford University School of Medicine. He served as the Director of the General Clinical Research Center and co-directed the Stanford University Center for Clinical and Translational Education Research (Spectrum), contributing to the research landscape from 1992 until 2017. Dr. Sikic's educational background includes an undergraduate degree from Georgetown University and an M.D. from the University of Chicago. After completing his residency in internal medicine at Georgetown, he engaged in a research fellowship in cancer pharmacology at the National Cancer Institute and subsequently joined the Stanford faculty in 1979. Over his career, he has authored over 250 publications and has been recognized with numerous accolades, including the Presidential Medal for Science and Medicine from the Government of Croatia in 2010. His research explores the mechanisms of drug resistance in cancer cells and the development of innovative cancer therapies, focusing particularly on anti-cancer drugs and their pharmacological properties. Dr. Sikic is known for his contributions to understanding multidrug resistance and has actively participated in key advisory roles, such as chairing the Scientific Program Committee for the American Society of Clinical Oncology. He has played a pivotal role in various clinical trials aimed at advancing cancer treatment.
Stanford University • Stanford, California
Professor of Medicine in the Division of Oncology, focusing on cancer research and pharmacology.
General Clinical Research Center, Stanford University • Stanford, California
Directed the General Clinical Research Center.
Stanford University Center for Clinical Translational Education Research • Stanford, California
Co-directed the center aimed at enhancing clinical translational research.
Patent related to resistance mechanisms in cancer treatment.
Patent concerning cyclosporin modulation in cancer pharmacology.
The Computer Science department emphasizes research potential. GRE General is currently optional but recommended for some tracks.